Omega Diagnostics Group - Re: ODX Stream Log - finnCap's note out today on...

Live Discuss Polls Ratings Documents
11:42 28/06/2016

finnCap's note out today on research tree "Omega Diagnostics’ FY2016 results were in line with our expectations. Sales rose 5% (7% CER), driven by Food Intolerance (+19%) which offset expected declines in Allergy and Autoimmune and a flat Infectious Disease performance. We expect Allersys to launch in FY 2017. Moreover, there is a clearer roadmap to market for Visitect CD4, for which some of its technical challenges have seemingly been resolved. This enables management to invest more confidently for growth, which is reflected in our forecasts."